UK markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.86-0.20 (-2.83%)
At close: 04:00PM EST
6.86 0.00 (0.00%)
After hours: 04:01PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 425.74M
Enterprise value 512.76M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.07
Price/book (mrq)N/A
Enterprise value/revenue 4.92
Enterprise value/EBITDA -5.33

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 3-60.60%
S&P500 52-week change 314.85%
52-week high 321.30
52-week low 36.39
50-day moving average 38.57
200-day moving average 313.33

Share statistics

Avg vol (3-month) 31.15M
Avg vol (10-day) 3860.25k
Shares outstanding 547.36M
Implied shares outstanding 6N/A
Float 842.98M
% held by insiders 13.02%
% held by institutions 1106.04%
Shares short (13 Jan 2022) 44.57M
Short ratio (13 Jan 2022) 43.62
Short % of float (13 Jan 2022) 49.87%
Short % of shares outstanding (13 Jan 2022) 49.64%
Shares short (prior month 14 Dec 2021) 44.48M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin -159.85%
Operating margin (ttm)-128.36%

Management effectiveness

Return on assets (ttm)-23.26%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)104.15M
Revenue per share (ttm)2.26
Quarterly revenue growth (yoy)46.00%
Gross profit (ttm)55.5M
Net income avi to common (ttm)-166.48M
Diluted EPS (ttm)-3.61
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)167.61M
Total cash per share (mrq)3.54
Total debt (mrq)254.62M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.34
Book value per share (mrq)-1.54

Cash flow statement

Operating cash flow (ttm)-46.68M
Levered free cash flow (ttm)-35.42M